Compare Torrent Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs WOCKHARDT - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA WOCKHARDT TORRENT PHARMA/
WOCKHARDT
 
P/E (TTM) x 38.6 -109.8 - View Chart
P/BV x 9.8 2.4 401.5% View Chart
Dividend Yield % 0.6 0.0 39,321.4%  

Financials

 TORRENT PHARMA   WOCKHARDT
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
WOCKHARDT
Mar-18
TORRENT PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,9641,012 194.1%   
Low Rs1,245532 234.2%   
Sales per share (Unadj.) Rs453.4355.9 127.4%  
Earnings per share (Unadj.) Rs25.8-60.3 -42.8%  
Cash flow per share (Unadj.) Rs62.3-46.8 -133.2%  
Dividends per share (Unadj.) Rs17.000.01 170,000.0%  
Dividend yield (eoy) %1.10 81,768.5%  
Book value per share (Unadj.) Rs279.2257.8 108.3%  
Shares outstanding (eoy) m169.22110.63 153.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.52.2 163.2%   
Avg P/E ratio x62.2-12.8 -486.0%  
P/CF ratio (eoy) x25.8-16.5 -156.1%  
Price / Book Value ratio x5.73.0 192.0%  
Dividend payout %65.90 -397,430.0%   
Avg Mkt Cap Rs m271,51385,379 318.0%   
No. of employees `00013.66.3 217.4%   
Total wages/salary Rs m14,0389,371 149.8%   
Avg. sales/employee Rs Th5,642.66,295.0 89.6%   
Avg. wages/employee Rs Th1,032.41,498.3 68.9%   
Avg. net profit/employee Rs Th320.9-1,066.3 -30.1%   
INCOME DATA
Net Sales Rs m76,72839,369 194.9%  
Other income Rs m5711,202 47.5%   
Total revenues Rs m77,29940,571 190.5%   
Gross profit Rs m19,83118 108,363.9%  
Depreciation Rs m6,1771,495 413.1%   
Interest Rs m5,0382,555 197.2%   
Profit before tax Rs m9,187-2,830 -324.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,570-3,582 99.7%   
Tax Rs m1,254257 487.7%   
Profit after tax Rs m4,363-6,669 -65.4%  
Gross profit margin %25.80 55,601.3%  
Effective tax rate %13.6-9.1 -150.2%   
Net profit margin %5.7-16.9 -33.6%  
BALANCE SHEET DATA
Current assets Rs m50,37533,796 149.1%   
Current liabilities Rs m51,65326,917 191.9%   
Net working cap to sales %-1.717.5 -9.5%  
Current ratio x1.01.3 77.7%  
Inventory Days Days9279 116.0%  
Debtors Days Days6889 76.5%  
Net fixed assets Rs m83,64839,664 210.9%   
Share capital Rs m846553 153.0%   
"Free" reserves Rs m46,39727,968 165.9%   
Net worth Rs m47,24428,522 165.6%   
Long term debt Rs m39,12921,731 180.1%   
Total assets Rs m141,20981,620 173.0%  
Interest coverage x2.8-0.1 -2,626.2%   
Debt to equity ratio x0.80.8 108.7%  
Sales to assets ratio x0.50.5 112.7%   
Return on assets %6.7-5.0 -132.1%  
Return on equity %9.2-23.4 -39.5%  
Return on capital %12.3-7.7 -160.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,1039,807 225.4%   
Fx outflow Rs m5,5221,789 308.7%   
Net fx Rs m16,5818,019 206.8%   
CASH FLOW
From Operations Rs m17,981684 2,627.2%  
From Investments Rs m-2,4136,302 -38.3%  
From Financial Activity Rs m-13,145-7,695 170.8%  
Net Cashflow Rs m2,380-664 -358.5%  

Share Holding

Indian Promoters % 71.5 74.5 96.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 2.3 305.2%  
FIIs % 12.6 7.7 163.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 67,757 39.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SHASUN PHARMA  WYETH  GSK PHARMA  ALEMBIC  DR. REDDYS LAB  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 12, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS